Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
BIOGRAPHY
FEB 27, 2019 3:00 PM PST
Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Presented at:
Drug Discovery Virtual Event Series 2019
Speaker
Abstract
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different immune checkpoint modulators).
Learning Objectives:
1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
2. Presentation will also highlight key factors that influence in developing next generation ADCs.
You May Also Like
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
FEB 27, 2019 3:00 PM PST
Share
Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Presented at:
Drug Discovery Virtual Event Series 2019
Loading Comments...